Safety and efficacy of natalizumab in children with multiple sclerosisAngelo Ghezzi, Gıancarlo Comı, Carlo Pozzilli et al.|Neurology|2010Cited by 93
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosisMaria Pia Amato, María Trojano, Vincenzo Brescia Morra et al.|Brain|2020Cited by 90
COVID-19 Severity in Multiple SclerosisMaria Pia Sormani, Giovanna Borriello, Irene Schiavetti et al.|Neurology Neuroimmunology & Neuroinflammation|2021Cited by 74
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Diana Ferraro, Marta Simone et al.|JAMA Neurology|2021Cited by 62
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)Silvia Messina, Claudio Solaro, Isabella Righini et al.|PLoS ONE|2017Cited by 58